Sheena is a clinical epidemiologist whose research focus is the development and implementation of biomedical interventions to prevent, or at least reduce the risk of acquiring HIV.
Since 1994, she has worked on Phase I/II HIV vaccine trials in Europe and Africa. Current collaborations include MucoVac, TaMoVac, CUTHIVac and the UK HIV Vaccine Consortium, all with Imperial College. From 2000, Sheena has been the co-Principal Investigator of the Microbicides Development Programme (MDP), a multi-disciplinary public-private partnership. The Phase III clinical trial enrolled 9,385 women through six research centres in Southern Africa and reported in 2009, disappointingly observing no benefit.
Four of six trials that have reported in full, or in part, have confirmed that tenofovir-based regimens can reduce the risk of HIV acquisition when taken by HIV negative individuals. This is highly relevant to the UK HIV epidemic and Sheena’s research interests have now expanded to encompass questions relevant to the implementation of oral pre-exposure prophylaxis (PrEP) in the UK. She is Chief Investigator on the PROUD trial, a UK pilot study in men who have sex with men.
Sheena has been a Consultant in HIV/ Genitourinary (GU) Medicine since 1991, initially at the Royal Devon and Exeter Hospitals and since 1996 at Chelsea & Westminster Hospital working at 56 Dean Street in Soho. She is Professor of Clinical Epidemiology at Imperial College.
To read more about Sheena's work and career, see her profile in The Lancet.
McCormack S, Fidler S, Fisher M. The British HIV Association/British Association for Sexual Health and HIV Position Statement on pre-exposure prophylaxis in the UK. Int J STD&AIDS, 2012 23:1-4.
Shattock RJ, Warren M, McCormack S, Hankins CA. Turning the tide against HIV. Science 2011, 333 (6038): 42-43.
Pool R, Montgomery C, Morar NS, Mweemba O, Ssali A, Gafos M, Lees S, Stadler J, Crook A, Nunn A, Hayes R, McCormack S. Assessing the accuracy of adherence and sexual behaviour data in the MDP301 vaginal microbicides trial using a mixed methods and triangulation model. PLoS One. 2010 Jul 21;5(7):e11632. PMID: 20657774.
McCormack S, Ramjee G, Kamali A, Rees H, Crook A, Gafos M, Jentsch U, Pool R, Chisembele M, Kapiga S, Mutemwa R, Vallely A, Palanee T, Sookrajh Y, Lacey CJ, Darbyshire J, Grosskurth H, Profy A, Nunn A, Hayes R, Weber J. PRO2000 vaginal gel for the prevention of HIV infection: results of the MDP301 Phase III randomised microbicide trial. The Lancet 2010 376: 1329-37.
McCormack S, Stöhr W, Barber T, Bart PA, Harari A, Moog C, Ciuffreda D, Cellerai C, Cowen M, Gamboni R, Burnet S, Legg K, Brodnicki E, Wolf H, Wagner R, Heeney J, Frachette MJ, Tartaglia J, Babiker A, Pantaleo G, Weber J. EV02: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 2008, 26(25):3162-74. PMID: 18502003.